Skip to main content

Table 2 Mortality rates in patients with AECOPD, any COPD, or Respiratory failure due to COPD, respectively, stratified according to suPAR and CRP quartilesa

From: Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD

 

AECOPD

any COPD

Respiratory failure

 

Survived

Died

p-value

Survived

Died

p-value

Survived

Died

p-value

30-day mortality

671 (93.6%)

46 (6.4%)

 

2338 (90.1%)

235 (9.1%)

 

210 (79.3%)

55 (20.7%)

 

 suPAR (ng/ml), median (IQR)

3.5 (2.6–4.9)

4.5 (3.5–5.8)

0.0004

3.6 (2.7–5.1)

5.7 (3.8–8.1)

< 0.0001

3.8 (2.8–5.1)

4.1 (3.0–6.3)

0.14

 CRP (mg/L), median (IQR)

21 (5–75)

46 (15–86)

0.03

13 (4–57)

71 (20–160)

< 0.0001

21.5 (6–80)

43 (8.5–115)

0.14

 suPAR quartile 1

176 (97.2%)

5 (2.8%)

 

594 (97.2%)

17 (2.8%)

 

58 (82.9%)

12 (17.1%)

 

 suPAR quartile 2

176 (95.6%)

8 (4.4%)

 

634 (94.6%)

36 (5.4%)

 

51 (79.7%)

13 (20.3%)

 

 suPAR quartile 3

165 (91.2%)

16 (8.8%)

 

583 (91.2%)

56 (8.8%)

 

54 (81.8%)

12 (18.2%)

 

 suPAR quartile 4

154 (90.1%)

17 (9.9%)

0.01b

527 (80.7%)

126 (19.3%)

< 0.0001b

47 (72.3%)

18 (27.7%)

0.44b

 CRP quartile 1

186 (96.9%)

6 (3.1%)

 

622 (96.4%)

23 (3.6%)

 

57 (80.3%)

14 (19.7%)

 

 CRP quartile 2

166 (94.3%)

10 (5.7%)

 

619 (95.5%)

29 (4.5%)

 

54 (85.7%)

9 (14.3%)

 

 CRP quartile 3

154 (90.1%)

17 (9.9%)

 

577 (89.6%)

67 (10.4%)

 

51 (77.3%)

15 (22.7%)

 

 CRP quartile 4

165 (92.7%)

13 (7.3%)

0.06b

520 (81.8%)

116 (18.2%)

< 0.0001b

48 (73.8%)

17 (26.2%)

0.40b

90-day mortality

621 (86.6%)

96 (13.4%)

 

2203 (85.6)

370 (14.4%)

 

194 (73.2%)

71 (26.8%)

 

 suPAR (ng/ml), median (IQR)

3.3 (2.6–4.6)

4.7 (3.7–6.2)

< 0.0001

3.6 (2.7–5.0)

5.4 (3.8–7.5)

< 0.0001

3.7 (2.8–5.0)

4.2 (3.0–6.3)

0.03

 CRP (mg/L), median (IQR)

20 (5–75.5)

41 (13–73)

0.005

12 (3–54)

61 (16–130)

< 0.0001

19 (6–82)

43 (7–110)

0.11

 suPAR quartile 1

174 (96.1%)

7 (3.9%)

 

583 (95.4%)

28 (4.6%)

 

55 (78.6%)

15 (21.4%)

 

 suPAR quartile 2

169 (91.9%)

15 (8.1%)

 

614 (91.6%)

56 (8.4%)

 

49 (76.6%)

15 (23.4%)

 

 suPAR quartile 3

149 (82.3%)

32 (17.7%)

 

540 (84.5%)

99 (15.5%)

 

49 (74.2%)

17 (25.8%)

 

 suPAR quartile 4

129 (75.4%)

42 (24.6%)

< 0.0001b

466 (71.4%)

187 (28.6%)

< 0.0001b

41 (63.1%)

24 (36.9%)

0.18b

 CRP quartile 1

178 (92.7%)

14 (7.3%)

 

605 (93.8%)

40 (6.2%)

 

52 (73.2%)

19 (26.8%)

 

 CRP quartile 2

155 (88.1%)

21 (11.9%)

 

593 (91.5%)

55 (8.5%)

 

51 (81.0%)

12 (19.0%)

 

 CRP quartile 3

133 (77.8%)

38 (22.2%)

 

537 (83.4%)

107 (16.6%)

 

46 (69.7%)

20 (30.3%)

 

 CRP quartile 4

155 (87.1%)

23 (12.9%)

0.0004b

468 (73.6%)

168 (26.4%)

< 0.0001b

45 (69.2%)

20 (30.8%)

0.41b

  1. aThe cut-offs for the suPAR quartiles in each population were as follows: AECOPD: Q1: ≤2.6 ng/ml, Q2: 2.7–3.5 ng/ml, Q3: 3.6–5.0 ng/ml, Q4: > 5 ng/ml. Any COPD: Q1: ≤2.7 ng/ml, Q2: 2.8–3.7 ng/ml, Q3: 3.8–5.3 ng/ml, Q4: ≥5.4 ng/ml. Respiratory failure: Q1: ≤2.8 ng/ml, Q2: 2.9–3.8 ng/ml, Q3: 3.9–5.3 ng/ml, Q4: ≥5.4 ng/ml
  2. The cut-offs for the CRP quartiles in each population were as follows: AECOPD: Q1: < 6 mg/l, Q2: 6–23 mg/l, Q3: 24–74 mg/l, Q4:≥75 mg/l. Any COPD: Q1: < 4 mg/l, Q2: 4–14 mg/l, Q3: 15–64 mg/l, Q4: ≥65 mg/l. Respiratory failure: Q1: < 7 mg/l, Q2: 7–25 mg/l, Q3: 26–85 mg/l, Q4: ≥86 mg/l.
  3. bChi2-tests by increasing suPAR and CRP-quartiles
Back to article page